Enzon Pharmaceuticals Inc
ENZN
Market Cap$6.1M
Close$
$0.63
669.7% upside
Current Fair Value
669.7% upsideUndervalued by 669.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.10 Million |
|---|---|
| Enterprise Value | $-38,530,849.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.01 |
| Beta | 0.24 |
| Outstanding Shares | 74,215,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -92.49 |
|---|---|
| PEG | 35.07 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1481.96 |
| Enterprise Value to EBIT | -253.49 |
| Enterprise Value to Net Income | 583 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Enzon Pharmaceuticals Inc
CEO: Andrew Rackear Enzon Pharmaceuticals, Inc is a pharmaceutical company engaged in developing therapeutics to patients whose needs are unmet. Its headquarters is now in Piscataway, New Jersey. The company is a publicly traded company on NASDAQ under the ...